EXIR is leaded and guided by a Board of Directors and Executive Management group. The Board of Directors is responsible for the overall management of EXIR. The Executive management has the day-to-day management responsibility. Basic principles for good corporate governance of EXIR management team include universal and essential values such as transparency, accountability, openness, integrity and responsibility put into practice in a triangle combining statutory, self regulation and ethics. In order to be socially responsible, we acknowledge a responsibility broader than our legal responsibility to our employees, creditors, suppliers, customers and community.

With the approval of the Reception Board of Tehran Stock Exchange Market Organization, EXIR was listed among accepted companies in year 2000.
Social Security Investment Co. (SSIC), the largest holding company in Iran, is the main shareholder of EXIR. Pharmaceutical sector is one of the major fields of its investment. SSIC presently owns and controls 20 pharmaceutical manufacturing companies and possesses about 45% share of total pharmaceutical production in Iran. Other main shareholders are Daroupkhsh Co. and Social Security Organization.
EXIR is organized under Iranian law as a public share company. The shareholders have the ultimate authority over the company, and they exercise their right to make decisions affecting EXIR at general meetings.

The Board of Directors supervises the performance of the company, its management and organization on behalf of the shareholders. It also participates in determining the company strategy.

General meetings are called with approximately 1 month’s notice, and the agenda has been prepared before, is discussed. The annual general meeting approves the annual financial report. Further, the general meeting elects five directors and one external auditing firm.
All shareholders attend the general meetings and ask questions, and EXIR strives to reply to all of them.
The Board currently consists of five directors. They are elected by shareholders at general meetings. They serve for a 2-year term and can be re-elected at the general meeting. The Board actively contributes to developing the company as a focused global pharmaceutical company and supervises Executive management in its decisions and operations. The Board ordinary meets every 1 month.
The chairman and the deputy chairman constitute the chairmanship of the Board of Directors. They carry out a number of administrative tasks, such as supervising the appropriate balance between determination of overall strategy and the financial and managerial affairs of the company.

In EXIR a well balanced evaluation system is used as a basis for carrying out quality controls. Uncompromising control of every phase of production, all the way from row materials to finished products, is carried out in the Company’s Quality control laboratories. Mostly the company’s R&D department is responsible for research projects and all of the processes meet GMP requirements and WHO regulations.